Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes

“…Acalabrutinib treatment similarly ameliorates LPS/galactosamine-induced infiltration of macrophages and reduces serum levels of MCP-1 in a mouse model of hepatic damage by inhibiting TLR4-induced NF-κB activation (Shaker et al, 2020). Interestingly, a number of case studies have reported the effects of ibrutinib or acalabrutinib on attenuating inflammatory cytokine and chemokine release, lung injury and respiratory failure in patients with severe COVID-19 (Lin et al, 2020;Rada et al, 2020;Scarfo et al, 2020;Treon et al, 2020;Alsuliman et al, 2021;Benner and Carson, 2021;Fiorcari et al, 2021;Molina-Cerrillo et al, 2021). Specifically, Roschewski et al (2020) found that acalabrutinib treatment improves oxygenation and reduces IL-6 production in monocytes of patients with severe COVID-19.…”

COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease

“…With the recent emergence of new SARS-CoV-2 variants, many hematology teams are facing unconventional situations and are being asked to modify their practices in order to offer the best medical care for their patients [1] , [2] , [3] . In this context, hematopoietic stem cell transplantation (HSCT) for autoimmune disease patients represent one of the most vulnerable groups of patients due to preexisting comorbidities and the acquired immunodepression during conditioning with chemotherapy [4] .…”

Two years of COVID-19: A summary about the implication of current research in translational medicine in the efforts against the pandemic

“…Cancer treatment complications in the time of COVID-19 were also presented by two letters to the editor published in October 2021. The first is about ibrutinib treatment for mantle cell lymphoma patients in the time of COVID-19 from a clinical observation point of view, [9] while the second discussed special aspects of COVID-19 management in patients during autologous stem cell transplant for autoimmune diseases. [10] …”